Lung Cancer News

CHICAGO — Acetaminophen suppressed antitumor immunity in a cohort of patients with cancer, according to study results presented during ASCO Annual Meeting.

CHICAGO — Adagrasib demonstrated promising efficacy for pretreated patients with advanced or metastatic non-small cell lung cancer who harbor KRASG12C mutations, according to study results presented at ASCO Annual Meeting.

Both visual and quantitative CT assessments of emphysema were associated with greater odds of lung cancer, researchers reported in Radiology.

CHICAGO — Patients and prescribers should be more aware of the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy, according to retrospective study results presented at ASCO Annual Meeting.

CHICAGO — During the ASCO Annual Meeting, Healio honored our inaugural Healio Disruptive Innovators in hematology/oncology.

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.

CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.

Charu Aggarwal, MD, MPH, shared with Healio non-small cell lung cancer studies she is most looking forward to seeing the results of at the ASCO Annual Meeting, taking place June 3-7 in Chicago.

The inclusion of a smoking cessation tool into electronic health records increased self-reported patient quit rates by more than 5 percentage points, according to study results.